According to the Wisdom Financial APP, Kelun Botai Biopharmaceutical-B (06990) has rebounded two days in a row, rising nearly 10% in early trading. The stock fell nearly 30% in the previous month. As of the press release, it rose 9.14%, reporting at HKD 155.2 yuan, with a turnover of 0.232 billion Hong Kong dollars.

On the news front, Kelun Botai Biopharmaceutical marks the first anniversary of listing and welcomes the lifting of restrictions on over 0.1 billion H shares today. According to a previous announcement issued by the company, the last day of the lock-up period for the controlling shareholders, initial public offering investors and other existing shareholders, including Kelun Pharmaceutical, Wang Jingyi, Merck, and Advanced Manufacturing Industry Investment Fund, is July 11. It is reported that Kelun Pharmaceutical, the controlling shareholder, will lift the ban on 57.7778 million shares; Wang Jingyi will lift the ban on 2.85 million shares; and pre-listing investors will lift the ban on 40.1836 million shares.

Kelun Botai Biopharmaceutical's 2023 financial report shows that the company achieved revenue of RMB 1.54 billion during the period, an increase of 91.62% year-on-year; the shareholder's deficit shrank to RMB 0.574 billion, a decrease of 6.81% year-on-year. Pacific Securities previously pointed out that Kelun Botai's commercialization is imminent, and its rich pipeline reserves have laid a solid foundation for the company's development. The company has 4-5 pipelines that will soon be commercialized, including two core ADC products SKB264 and A166, which are expected to turn losses into profits in 2027.